spacer
home > ict > winter 2013 > reach for the sky
PUBLICATIONS
International Clinical Trials

Reach for the Sky

It is hard to believe that, in a world where we can instantly send a video from a laptop in a rural US town all the way to a smartphone on a South Pacific beach, many pharma companies still share clinical documentation via email, or worse. Trial managers sometimes fly halfway around the world to view a study’s documentation, just to demonstrate they are meeting regulations and prepare for inspection. These inefficiencies are adding tremendous costs, especially to Phase 3 trials, which could easily entail more than 150 sites across 25 countries.

However, the take-up of cloud technologies is bringing a welcome change to clinical operations. Many pharma chief information officers and IT professionals are excited about its promise. Concerns about the open nature of the cloud initially slowed adoption, but the benefi ts are now being fully recognised by pharma and biotech companies.

In fact, the cloud has become the preferred software platform for life sciences sales and marketing departments,and is growing rapidly throughout the clinical sphere (1). Medidata Solutions, a leading global provider of cloudbased solutions for clinical research, continues to enjoy year-over-year increases in adoption of its cloud-based platform (2).

Business Benefits

The cloud provides many business benefits that should be considered by clinical operations or document management teams – especially given the complexity of today’s trials and the steady increase in partnering with contract research organisations (CROs). GBI Research estimates that the global R&D outsourcing market is expected to reach 37.1 per cent of the total R&D expenditure by 2018 (3). With so many players in different locations worldwide – all under the watchful eye of health authorities – the need for systems that are cost-efficient, highly accessible and easily configurable (characteristics that are innately ‘cloud’) is acute.

“Cloud is a consistent trend that is making an impact on both the data collection side of trials and the accompanying ecosystem of tools. It will become the most prominent software deployment strategy in all enterprises, including life sciences,” says Rick Morrison, head of Comprehend Systems. “The companies in the cloud can take advantage of significant economies of scale, including security and redundancy. Cloud networks typically require no upfront capital expense, which allows sponsors to simply pay for what they use – nothing more, nothing less” (4).

One of the areas where clinical operations teams have the most to gain from moving to the cloud is the management of the trial master file (TMF). With all of the content it must capture from disparate sources, a cloud-based electronic TMF system (eTMF) gives clinical operations managers potentially trial-changing benefits such as streamlined processes for faster start-up and time to market, increased trial oversight and control, and improved collaboration for better quality documentation and milestone adherence.

Centralised Documentation

In all trial phases, clinical studies require focused collaboration among the sponsoring company, CROs, investigators, ethics committees, and many other contributors. Trials need to meet the requirements for regulatory oversight and documentation every step of the way, often for multiple regions. Thousands of documents are required just to launch a new study, and the time required to keep it all straight creates considerable administrative overhead and costs.

In response, we are experiencing an industry shift toward systems that support an eTMF. In fact, 2012 survey data from the DIA TMF Reference Model group showed a 12 per cent increase in the number of respondents planning, building or evaluating an eTMF. Furthermore, a cloud-based eTMF provides superior accessibility and availability over traditional eTMF solutions that are managed internally by sponsors or CROs.

Cloud technology – where software is web-based, rather than installed on individual hard drives or in a sponsor or CRO’s data centre – enables document exchange on demand, wherever permissioned users can connect to the internet. Cloud-based eTMF systems provide a centralised, secure place for all clinical players to share their documentation in a standardised and fully reportable system. It can be quickly accessed from any device, anywhere in the world. Necessary changes can be made at any point in the process, and saved back to the cloud repository.

Collaborative Workflow

This is quite different from traditional systems, where lack of access forces each party to maintain their own copies of the documents. The manual hand-offs (email, courier and so on) of these documents can create information overload and propensity for error. Inaccessibility also means that simple questions like “What documents are missing?” and “Has the contract for the site been signed?” take far too long to answer.

The cloud, on the other hand, allows collaborative workflow between sponsors, CROs and investigators, while maintaining a single, consistent audit trail of activities and updates. Everyone works ‘on the same page’, with complete visibility on all aspects of the study process. This empowers everyone involved in the trial, by giving them direct and real-time access to the information they need in order to understand core metrics and milestones such as site status or inspection readiness.

System Efficiencies

Workflow efficiencies are paramount in clinical trials. Ultimately, these workflows help sponsors meet governance, risk and compliance obligations, too. Cloud-based eTMFs that are accessible by all parties naturally incorporate participants into a single workflow structure. The software then automates the flow of documents and tasks between participants to help ensure trial documentation processes are followed to completion. Traditional systems where workflows and TMF documents are tracked manually, in contrast, can lead to inaccuracies, missing information and an overall lack of document control.

“Now, with a bird’s eye view of all trial participants and processes, management has a greater opportunity to identify bottlenecks or inefficiencies, so they can improve the clinical process,” comments Marcus Thornton of Medidata Solutions.

More important today than ever, the global accessibility of the cloud helps sponsors overcome the difficulties of coordinating trial materials across worldwide locations. A cloud eTMF system is structurally designed to make it easy to provision new users when site locations are added, and to automatically include them in the workflows for that trial.

Faster Start-Up

Implementation of cloud-based eTMF systems can take as little as four weeks. Because the system infrastructure and software is maintained by the vendor, there is nothing to install. In addition, site personnel can be added to the system in minutes, rather than days or weeks.

Cloud applications can be tailored to each individual sponsor without customised code, enabling sponsors to easily configure the out-of-the-box application to reflect their company’s standard operating procedures and study protocols. Combined, these features dramatically speed study start-up. “This allows for reduced IT burden and greater accessibility for the clinical team, thereby reducing costs and driving further operational efficiencies,” adds Marcus Thornton.

Throughout the clinical trial, sponsors can respond to changes much more quickly when the eTMF system is in the cloud. Most features are configurable by business administrators within the clinical operations team. So, for example, when there is a change in protocol or a need to add new pick-list items, the changes can be made simply.

Bright Future

Worldwide, regulators are recognising that there is a future for life sciences in the cloud, and they are increasingly focused on how to adapt their oversight practices to address the industry shift. This is a necessary step toward more clearly defined rules for use of cloud-based systems in the clinical development process.

The 2011 update of the European Union Guidance on Computerised Systems (EU Annex 11) has provided clarity to both sponsors and vendors on the validation requirements for cloud-based systems, and is influencing the US Food and Drug Administration. As many companies adopt cloud-based eTMF systems, their successful use is helping to dispel any concerns about compliance or security.

Can the life sciences industry embrace the cloud and take advantage of the efficiencies provided by this technology? The answer is yes – and it must. Paper files and locally installed software tools are no longer manageable under today’s cost pressures and the urgency to complete worldwide studies successfully. The cloud is key to truly achieving scalability and efficiencies across clinical trials.

References

1. MarketScape Worldwide Life Sciences CRM software vendor assessment, IDC Health Insights, July 2013

2. Vendor assessment 2012: Top ten life science software vendors, IDC Health Insights, March 2013 Visit: http://idcdocserv.com/HI240273e_medidata

3. Yahoo Finance, CROs market to 2018, press release posted by GBI Research. Visit: http://fi nance.yahoo.com/news/ contract-research-organizations-cros-market-131800278.html

4. Brooks K, CRO outlook and opportunities, ContractPharma.com, June 2013. Visit: www.contractpharma.com/issues/ 2013-06/view_features/cro-outlook-market-trends/ #sthash.DnLFqWec.dpuf


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jennifer Goldsmith, Vice President of Vault at Veeva Systems, is a pioneering thinker with a long history of leadership in life sciences and technology. She has worked across the value chain from early R&D to commercial operations and, most recently, has spearheaded the development of the first cloud-based regulated content management solution for the life sciences industry with the Vault product line. Jennifer is a member of the Healthcare Advisory IT Committee at Pennsylvania Bio, a featured speaker for the Drug Information Association and Healthcare Businesswomen’s Association, and a published author.
spacer
Jennifer Goldsmith
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Successfully managing the unique demands of cell therapy supply chains

PCI Pharma Services

Cell therapy professionals joined a specialist webinar by industry experts from PCI Clinical Services and TrakCel, addressing the unique complexity of an autologous therapy supply chain. Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, Associate Director, Technical Services, PCI Clinincal Services, and Dr. Matthew Lakelin, Vice President, Scientific Affairs and Business Development, TrakCel . Here, we present the white paper from that webinar event.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement